Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America-Reference-Cited by-同舟云学术

Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America

Published:2020-10 Issue: Volume:45 Page:102404
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Burt Richard K^ORCID,Tappenden Paul,Han Xiaoqiang,Quigley Kathleen,Arnautovic Indira,Sharrack Basil,Snowden John A,Hartung Daniel^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference46 articles.

1. Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis;Abrahamsson;Brain,2013

2. The cost burden of multiple sclerosis in the United States: a systematic review of the literature;Adelman;J. Med. Econ.,2013

3. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis;Arnold;BMC Neurol.,2014

4. Arroyo R., Bury D.P., Guo J.D., Margolin D.H., Melanson M., Daizadeh N., Cella D. Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis. Mult. Scler. J.. 2019May 30;1352458519849796 [Epub ahead of print).

5. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research?;Bevan;JAMA Neurol.,2014

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates;Multiple Sclerosis and Related Disorders;2024-08

2. Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-04

3. Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial;BMJ Open;2024-02

4. Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis;Neurological Sciences;2024-01-26

5. Therapeutic Strategies and Ongoing Research;Nutritional Neurosciences;2024